DIANA Biotechnologies, s.r.o. was established in 2018 as a spin-off company of the Institute of Organic Chemistry and Biochemistry (IOCB), Academy of Sciences in Prague, aiming to build on its global reputation and a strong track record in drug discovery. We have raised a substantial amount of venture capital funding and were awarded an exclusive global right for the DIANA technology.

Combining in our team a unique set of expertise in medical & organic chemistry, biochemistry, and pharmacology we are set to unleash the power of DIANA technology in both areas of clinical diagnostics and drug discovery.

In our diagnostics unit, we are building a portfolio of detection assays utilizing the DIANA’s ultra-high sensitivity, allowing the detection of medically relevant targets from a tiny amount of sample. Our drug discovery unit is providing complex CRO services ranging from assay development, HTS screening of small-molecular libraries and ADME pharmacology testing. Utilizing our collaborations, we are also developing some of our own early drug-discovery programs.

The company is now based in its own research facility in a biotechnology hub in Vestec near Prague and has established collaborations with range of industrial and academic partners.

Open vacancies